Compare Adaptive Biotechnologies Corp (ADPT) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs JPMorgan Chase & Co — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while JPMorgan Chase & Co trades at $362.6 (market cap $962.37B). The key difference: JPMorgan Chase & Co is far larger — about 238.2× Adaptive Biotechnologies Corp's market cap, and JPMorgan Chase & Co pays a 1.66% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | JPM | |
|---|---|---|
Market Cap | $4.04B | $962.37B |
Sector | Health | Financials |
52-Week High | $25.45 | $362.04 |
52-Week Low | $12.30 | $282.84 |
Enterprise Value | $4.10B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, with a bullish technical signal from moving averages and a consensus analyst price target of $374.18. Recent earnings have shown strength with beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue and net income have grown steadily, with 2025 revenue at $181.85B and net income at $57.05B, though cash flow from operations remains negative. The stock exhibits strong institutional interest and a moderate buy rating from analysts.
The outlook for JPM is positive, supported by robust profitability metrics like an 18.43% ROE and a net income margin of 33.38%. Key risks include geopolitical tensions impacting banking sectors and persistent negative operating cash flows. Upside potential exists if the company meets or exceeds future earnings expectations, with the next catalyst being Q3 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
